GlassScriptPhysician profile
Edith Linville
NPI 1316496326
$5,535.35
in general payments reported to CMS, 2019-2025
22 companies · $856 in 2025
The $856 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,341 · 2022: $1,028 · 2023: $1,132 · 2024: $1,179 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,160 · Education: $6.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.28 |
| Education | $6.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $782.27 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $749.09 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $710.94 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $685.52 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $439.00 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $409.55 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $393.64 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $389.60 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $281.68 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $276.19 | 2024-2025 | Hetlioz, Fanapt |
| Indivior INC. | $100.65 | 2022-2024 | Sublocade |
| Axsome Therapeutics, INC. | $78.82 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $50.86 | 2024-2025 | Cobenfy |
| Corium, LLC | $32.73 | 2023 | Azstarys |
| Tris Pharma INC | $24.54 | 2025 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $24.20 | 2025 | Erzofri Extended-Release |
| Gilead Sciences, INC. | $22.08 | 2023 | |
| Ironshore Pharmaceuticals INC. | $20.03 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.94 | 2025 | Qelbree |
| Orexo US, INC. | $16.46 | 2023 | Zubsolv |
| Noven Therapeutics, LLC | $15.45 | 2024 | Secuado, Xelstrym |
| Tms Neurohealth Centers INC. | $13.11 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Linville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.